Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/resp.14087 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The utility of infectious disease modelling in informing decisions for outbreak response: A scoping review.
PLOS Glob Public Health
September 2025
Centre for International Health Protection, Robert Koch Institute, Berlin, Germany.
Infectious disease modelling plays a critical role in guiding decisions during outbreaks. However, ongoing debates over the utility of these models highlight the need for a deeper understanding of their exact role in decision-making. In this scoping review we sought to fill this gap, focusing on challenges and facilitators of translating modelling insights into actionable policies.
View Article and Find Full Text PDFOrganizational barriers and recommendations for colorectal cancer survivorship care in Thailand: A qualitative study using the consolidated framework for implementation research.
Eur J Oncol Nurs
August 2025
School of Nursing, Columbia University, New York, NY, USA.
Purpose: Colorectal cancer survivors often face complex, long-term healthcare needs that are not adequately addressed, especially in low- and middle-income countries. Organizational barriers can significantly impede the delivery of survivorship care, but these challenges remain underexplored. This study aimed to explore healthcare providers' perspectives on organizational barriers and offer recommendations for improving colorectal cancer survivorship care in Thailand.
View Article and Find Full Text PDFEndogenous Aβ and Exogenous Wheat Gluten Nanostructures: Understanding Peptide Self-Assembly in Disease.
ACS Nano
September 2025
Bielefeld University, Faculty of Chemistry, Universitätsstr. 25, 33615 Bielefeld, Germany.
The self-assembly of endogenous and exogenous peptides into proteolysis-resistant oligomers can trigger toxic cellular events and diseases. In Alzheimer's disease (AD), the structural polymorphisms of endogenous amyloid-β (Aβ) 1-40 and 1-42 aggregates are essential for their neurotoxic effects. Recent findings on structural differences between brain-derived and fibrils underscore the need to improve the molecular and supramolecular models of diseases, for example, by stabilizing monomer conformations that lead to disease-relevant structures.
View Article and Find Full Text PDFRecommendations for a core assessment set for neurological physiotherapy entry-level education in Austria - a multistage process including a Delphi study.
BMC Med Educ
August 2025
Clinic for Rehabilitation Muenster, Department of Rehabilitation Science, Muenster, Austria.
Background: Standardised assessments are essential for diagnosing conditions, evaluating therapy, and formulating prognoses within physiotherapy. However, due to various barriers, including lack of knowledge, accessibility issues, and time constraints their routine use remains inconsistent. Defining a core set of standardised assessments for entry-level education is crucial in addressing these challenges.
View Article and Find Full Text PDFLimb-Girdle Muscular Dystrophy Scientific Workshop: A Multistakeholder Discussion Focused on Charting the Path Forward for Drug Development.
Neurol Clin Pract
October 2025
The Speak Foundation, Tallahassee, FL.
Limb-girdle muscular dystrophy (LGMD) refers to a group of muscular dystrophies that generally result in weakness and loss of limb-girdle muscles, leading to severe disability and early mortality due to cardiac and respiratory complications. Heterogeneity across and within individual LGMD subtypes in addition to variability in progression rates presents significant challenges to traditional drug development approaches for these diseases. In an effort to discuss these challenges, as well as opportunities in support of advancing drug development for LGMD, on February 8, 2024, The Speak Foundation assembled a multistakeholder group consisting of academic medical experts, patients and caregivers, patient advocacy organizations, senior leaders from the US Food and Drug Administration, and commercial drug developers.
View Article and Find Full Text PDF